BioLife Solutions CHRO Executes Small 10b5-1 Sale for Tax Withholding

Rhea-AI Filing Summary

BioLife Solutions Inc. (BLFS) – Form 4 filing: Chief Human Resources Officer Sarah Aebersold sold 198 shares of common stock on 7 July 2025 at $22.27 per share under a pre-established Rule 10b5-1 trading plan. The sale was executed to cover tax-withholding obligations associated with previously vested restricted stock. After the transaction, the officer still owns 78,523 shares, which continue to be held directly. No derivative security activity was reported.

The transaction represents <0.3% of the insider’s total direct holdings and does not indicate a change in her overall investment thesis or role at the company. As such, the filing is considered routine and of low financial materiality for most investors.

Positive

• Pre-planned 10b5-1 trade signals adherence to insider-trading safeguards and reduces perception of opportunistic selling.
• Insider retains 78,523 shares, maintaining substantial alignment with shareholder interests.

Negative

• Insider sale, although small, can still be interpreted as a marginal negative signal by some investors.

Insights

Securities Analyst

TL;DR: Minor insider sale, routine, limited market impact.

The 198-share sale totals roughly $4,400—a de-minimis amount relative to both Aebersold’s 78.5 k share position and BLFS’s average daily volume. Executed under a 10b5-1 plan and explicitly for tax-withholding, it raises negligible concerns about insider sentiment. I view the event as non-impactful to valuation or near-term trading dynamics.

Corporate Governance Expert

TL;DR: Governance-friendly disclosure; sale aligned with policy.

The filing demonstrates proper use of a pre-arranged 10b5-1 plan and timely Section 16 reporting, supporting governance best practices. Insider retains >99% of her stake, mitigating signaling risk. I classify this as routine compliance with no governance red flags.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aebersold Sarah

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2025		S(1)		198	D	$22.27	78,523	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Sarah Aebersold	07/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BLFS shares did Sarah Aebersold sell?

She sold 198 common shares.

At what price were the BLFS shares sold?

The shares were sold at $22.27 per share.

What is Sarah Aebersold's remaining BLFS share ownership after the sale?

She now directly owns 78,523 shares of BioLife Solutions.

Why was the sale executed under Rule 10b5-1?

The 10b5-1 plan was adopted to cover tax-withholding obligations tied to restricted-stock vesting.

Does this Form 4 indicate any derivative transactions?

No; the filing reports no derivative security activity.